Inhibition of mammalian target of rapamycin induces phenotypic reversion in three-dimensional cultures of malignant breast epithelial cells
Ross Booth, Soonjo Kwon, Eric Monson
DOI: 10.4236/jbise.2010.35066   PDF    HTML     4,003 Downloads   8,010 Views  


Inhibition of mammalian target of rapamycin (m- TOR) is a potential method for cancer treatment. Effects of rapamycin (RAP) on the reversion of malignant breast epithelial cells were investigated on three-dimensional (3D) basement membrane extract (BME) cultures. Through continuous exposure to 20 nM of RAP, cell colony size was significantly reduced in 3D BME cultures of malignant breast epithelial cells, while normal cell colony size appeared unaffected. In unfixed 3D BME cultures of normal and RAP-treated malignant breast epithelial cells, the presence of luminal cell death was confirmed by ethidium bromide and propidium iodide labeling. Increased structural organization was observed by im- munofluorescence staining of F-actin and β-catenin in RAP-treated malignant breast epithelial cells. In monolayer cultures of normal and malignant breast epithelial cells, continuous exposure to 20 nM of RAP increased caspase 3/7 activity and decreased proliferation. Reverse transcriptase polymerase ch- ain reaction (RT-PCR) array analysis indicated a fold increase in the expression of a number of proteins related to polarity, cell-cell adhesion, and cell-matrix adhesion in the presence of RAP. Our data showed that phenotypic reversion of malignancy can be ach- ieved through RAP exposure on 3D BME cultures. This 3D BME culture system will provide correct microenvironments for observing the effects of other mTOR inhibitors on phenotypic reversion of malignant breast epithelial cells.

Share and Cite:

Booth, R. , Kwon, S. and Monson, E. (2010) Inhibition of mammalian target of rapamycin induces phenotypic reversion in three-dimensional cultures of malignant breast epithelial cells. Journal of Biomedical Science and Engineering, 3, 476-483. doi: 10.4236/jbise.2010.35066.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Xu, F. and Burg, K.J. (2007) Three-dimensional polymeric systems for cancer cell studies. Cytotechnology, 54(3), 135-143.
[2] Lee, G.Y., Kenny, P.A., Lee, E.H. and Bissell, M.J. (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nature Methods, 4(4), 359-365.
[3] Debnath, J., Muthuswamy, S.K. and Brugge, J.S. (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods, 30(3), 256-268.
[4] Roskelley, C.D., Desprez, P.Y. and Bissell, M.J. (1994) Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both phy- sical and biochemical signal transduction. Proceedings of the National Academy of Sciences, 91(26), 12378-12382.
[5] Bello-DeOcampo, D., Kleinman, H.K., Deocampo, N.D. and Webber, M.M. (2001) Laminin-1 and alpha6 beta1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cells. Prostate, 46(2), 142-153.
[6] Reginato, M.J. and Muthuswamy, S.K. (2006) Illuminating the center: Mechanisms regulating lumen formation and maintenance in mammary morphogenesis. Journal of Mammary Gland Biology and Neoplasia, 11(3-4), 205- 211.
[7] Barcellos-Hoff, M.H., Aggeler, J., Ram, T.G. and Bissell, M.J. (1989) Functional differentiation and alveolar morph- ogenesis of primary mammary cultures on reconstituted basement membrane. Development, 105(2), 223-235.
[8] Kleinman, H.K., McGarvey, M.L., Liotta, L.A., Robey, P.G., Tryggvason, K. and Martin, G.R. (1982) Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry, 21(24), 6188-6193.
[9] Nelson, C.M. and Bissell, M.J. (2005) Modeling dynamic reciprocity: Engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Seminars in Cancer Biology, 15(5), 342-352.
[10] Liu, H., Radisky, D.C., Wang, F. and Bissell, M.J. (2004) Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. Journal of Cell Biology, 164, 603- 612.
[11] Wang, F., Hansen, R.K., Radisky, D., Yoneda, T., Barcellos-Hoff, M.H., Petersen, O.W., Turley, E.A. and Bissell, M.J. (2002) Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. Journal of the National Cancer Institute, 94(19), 1494-1503.
[12] Weaver, V.M., Petersen, O.W., Wang, F., Larabell, C.A., Briand, P., Damsky, C. and Bissell, M.J. (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. Journal of Cell Biology, 137(1), 231-245.
[13] Sabers, C.J., Martin, M.M., Brunn, G.J., Williams, J.M., Dumont, F.J., Wiederrecht, G. and Abraham, R.T. (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. Journal of Biological Chemistry, 270(2), 815-822.
[14] Sun, S.Y., Rosenberg, L.M., Wang, X., Zhou, Z., Yue, P., Fu, H. and Khuri, F.R. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Research, 65(16), 7052-7058.
[15] Vignot, S., Faivre, S., Aguirre, D. and Raymond, E. (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology, 16(4), 525-537.
[16] Heinonen, H., Nieminen, A., Saarela, M., Kallioniemi, A., Klefstrom, J., Hautaniemi, S. and Monni, O. (2008) Deciphering downstream gene targets of PI3K/mTOR/ p70S6K pathway in breast cancer. BMC Genomics, 9(4), 348-359.
[17] Bjornsti, M.A. and Houghton, P.J. (2004) The TOR pathway: A target for cancer therapy. Nature Reviews Cancer, 4(5), 335-348.
[18] Debnath, J., Walker, S.J. and Brugge, J.S. (2003) Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. Journal of Cell Biology, 163(2), 315-326.
[19] Gadducci, A., Cosio, S. and Genazzani, A.R. (2006) Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Reviews in Oncology/Hematology, 58(2), 242-256.
[20] Figlin, R.A., Brown, E., Armstrong, A.J., Akerley, W. and Benson, A.B., Burstein, H.J., Ettinger, D.S., Febbo, P.G., Fury, M.G., Hudes, G.R., Kies, M.S., Kwak, E.L., Morgan, R.J., Mortimer, J.J., Reckamp, K., Venook, A.P., Worden, F. and Yen, Y. (2008) NCCN task force report: mTOR inhibition in solid tumors. Journal of the National Comprehensive Cancer Network, 6(Suppl 5), S1-S20, S21-S22.
[21] Steelman, L.S., Stadelman, K.M., Chappell, W.H., Horn, S., Basecke, J., Cervello, M., Nicoletti, F., Libra, M., Stivala, F., Martelli, A.M. and McCubrey, J.A. (2008) Akt as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets, 12(9), 1139-1165.
[22] Pieretti-Vanmarcke, R., Donahoe, P.K., Pearsall, L.A., Dinulescu, D.M., Connolly, D.C., Halpern, E.F., Seiden, M.V. and MacLaughlin, D.T. (2006) Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proceedings of the National Academy of Sciences of the USA, 103(46), 17426-17431.
[23] Avellino, R., Romano, S., Parasole, R., Bisogni, R., Lamberti, A., Poggi, V., Venuta, S. and Romano, M.F. (2005) Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood, 106(4), 1400-1406.
[24] Mondesire, W.H., Jian, W., Zhang, H., Ensor, J., Hung, M.C., Mills, G.B. and Meric-Bernstam, F. (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clinical Cancer Research, 10(20), 7031- 7042.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.